Loading...
Loading...
NYMX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 5,074.0K |
| Operating I/L | -5,074.0K |
| Other Income/Expense | -12.0K |
| Interest Income | 0.0K |
| Pretax | -5,086.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -5,086.0K |
Nymox Pharmaceutical Corporation is a biopharmaceutical company specializing in research and development of drugs for the aging population. Its lead drug candidate, Fexapotide Triflutate (NX-1207), targets benign prostatic hyperplasia and low grade localized prostate cancer. The company also markets NicAlert and TobacAlert tests for tobacco product detection, as well as AlzheimAlert, a urine assay aiding in Alzheimer's disease diagnosis. Nymox Pharmaceutical Corporation generates revenue through the development and commercialization of these drug candidates and diagnostic tests, with a focus on addressing unmet medical needs in Canada, the United States, Europe, and internationally.
